Formulation Development and Evaluation of Metoprolol Succinate ER and Amlodipine Besilate Bilayer Tablet

According to the (WHO), hypertension is the most common cardiovascular condition in the world and there are about 600 million people at risk for heart attack, stroke and cardiac failure. High BP is estimated to cause 7.1 million deaths, about 13 percent of the global fatality total. It is believed this number will grow to approximately 11million by the year 2020.

The Formulation of Metoprolol Succinate ER and Amlodipine Besilate were prepared by using different polymer (HPMC, Methocel, Carbapol) with different diluents (MCC, Cellulose Phosphate, Starch, Croscarmalose Sodium) and then evaluated. The experimental work was divided into preformulation studies, formulation development, and evaluation. Standardization of drug and excipients confirmed the authentification of the samples. Thus it can be concluded that a stable bilayer tablet of Metoprolol succinate ER and Amlodipine besilate can be prepared by using HPMC K 15 M and carbomer as a polymer. It was found that the in vitro drug release of Metoprolol succinate ER was best explained by first order (r² =0. 9994), as the plots showed the highest linearity, followed by Higuchi's equation (r² = 0.9974) and zero-order (r² = 0.9471).